Identification of MicroRNAs regulating the developmental pathways of bone marrow derived mast cells by Xiang, Yang et al.
Identification of MicroRNAs Regulating the
Developmental Pathways of Bone Marrow Derived Mast
Cells
Yang Xiang1,2, Fiona Eyers1, Ian G. Young3, Helene F. Rosenberg4, Paul S. Foster1.*, Ming Yang1.*
1Centre for Asthma and Respiratory Disease, School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle and Hunter Medical Research
Institute, Callaghan, New South Wales, Australia, 2Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, People’s Republic
of China, 3Department of Molecular Bioscience, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia,
4 Inflammation Immunobiology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
Maryland, United States of America
Abstract
Background: MicroRNAs (miRNAs) play important roles in leukocyte differentiation, although those utilised for specific
programs and key functions remain incompletely characterised. As a global approach to gain insights into the potential
regulatory role of miRNA in mast cell differentiation we characterised expression in BM cultures from the initiation of
differentiation. In cultures enriched in differentiating mast cells we characterised miRNA expression and identified miRNA
targeting the mRNA of putative factors involved in differentiation pathways and cellular identity. Detailed pathway analysis
identified a unique miRNA network that is intimately linked to the mast cell differentiation program.
Methodology/Principal Findings: We identified 86 unique miRNAs with expression patterns that were up- or down-
regulated at 5-fold or more during bone marrow derived mast cells (BMMC) development. By employing TargetScan and
MeSH databases, we identified 524 transcripts involved in 30 canonical pathways as potentially regulated by these specific
86 miRNAs. Furthermore, by applying miRanda and IPA analyses, we predict that 7 specific miRNAs of this group are directly
associated with the expression of c-Kit and FceRIa and likewise, that 18 miRNAs promote expression of Mitf, GATA1 and c/
EBPa three core transcription factors that direct mast cell differentiation. Furthermore, we have identified 11 miRNAs that
may regulate the expression of STATs-3, -5a/b, GATA2 and GATA3 during differentiation, along with 13 miRNAs that target
transcripts encoding Ndst2, mMCP4 and mMCP6 and thus may regulate biosynthesis of mast cell secretory mediators.
Conclusions/Significance: This investigation characterises changes in miRNA expression in whole BM cultures during the
differentiation of mast cells and predicts functional links between miRNAs and their target mRNAs for the regulation of
development. This information provides an important resource for further investigations of the contributions of miRNAs to
mast cell differentiation and function.
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Introduction
Mast cells (MCs) are vital innate immune cells that are well-
known for their roles in the pathogenesis of immunoglobulin E
(IgE)-mediated disorders [1], while aberrant generation of MCs
can lead to disorders such as urticaria pigmentosa, systemic
mastocytosis and mast cell activation syndrome [2–4]. There is
also increasing recognition of the importance of MCs to both
innate and adaptive host defence against bacterial and parasitic
infection [5,6]. Thus, gaining a better understanding of pathways
that control MC differentiation will provide important insights into
the developmental programs of MCs in both health and in disease
states.
MCs are derived from pluripotent progenitors that originate in
bone marrow and that mature in most tissues but are particularly
enriched in the skin, tongue and in the mucosal layer of lung and
gastrointestinal tracts, under the control of specific growth and
differentiation factors [7]. Expansion of MCs predominantly and
synergistically relies on stem cell factor (SCF) and interleukin (IL)-3
[8]; both human and murine MCs express receptors for these two
cytokines [9,10]. Interestingly, IL-3 alone cannot generate MCs,
but this cytokine greatly enhances the numbers of differentiated
mast cells in tissue culture and in vivo [10,11]. By contrast, mice
with SCF receptor (c-Kit) mutations (Kitw/wv and Kitw-sh/w-sh
mice) have drastically reduced c-Kit/SCF signaling and demon-
strate a profound reduction in MCs [12,13]. Likewise, clinical
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evidence suggests that an activating mutation in the c-Kit gene is
strongly associated with systemic mastocytosis [14].
Although SCF and IL-3 drive the development of MCs, the
transcription factors and pathways that specifically control
differentiation have not been fully characterised. Currently,
microphthalmia-associated transcription factor (Mitf) is considered
as a central mediator of MC differentiation; Mitf is highly
expressed in both progenitor and fully differentiated MCs, while
notably absent in basophils [15]. Furthermore, accumulating
evidence suggests that the interplay between four co-re-regulatory
Figure 1. Expansion of BMMCs ex vivo. Bone marrow cells from BALB/c mice were cultured for 6 weeks as described in the Methods. MCs were
identified by (A) flow cytometry (c-Kit+FceRIa+ cells) and (B, C) toluidine blue staining. BM, bone marrow; w2 – w6, weeks 2–6; original magnification
of 1006. Values are presented as mean 6SEM (n= 4,6), **P,0.05 (w5 or w6 vs. other groups). *P,0.05 (w3 or w4 vs. BM and w2). #P,0.05 (w2 vs.
BM).
doi:10.1371/journal.pone.0098139.g001
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factors (e.g. the up-regulation of Mitf, GATA2 and PU.1 and the
down-regulation of CCAAT/enhancer binding protein a (C/
EBPa)) primarily regulates the development of the MC lineage
[16–18]. However, other intracellular signaling events such as
signal transduction and transcription (STAT) proteins, GATAs 1
and 3 and epigenetic regulators may also contribute to the
differentiation program [1,18].
MicroRNAs (miRNAs) are emerging as regulators of the
differentiation and proliferation of MCs [19]. MiRNAs are short
non-coding RNAs that regulate gene expression post-transcrip-
tionally by binding to the 39 untranslated region of target mRNAs,
thereby repressing protein production or destabilising target
transcripts [20–22]. The numerous roles of these small molecules
in the regulation of development, metabolism, organ function, and
disease pathogenesis have been documented extensively [20–22].
By contrast, much less is known about the miRNA networks that
control the differentiation and function of specific leukocyte
subsets. The aim of this study is to explore miRNA expression
profiling and analysis in silico in order to improve our understand-
ing of the factors that regulate MC growth and differentiation. As
a first approach, we have characterised the expression of miRNA
in whole BM cultures from the initiation of MC differentiation to
globally characterise the dynamics of miRNA expression in this
cellular milieu. The miRNA expression profile in cultures enriched
in differentiating MCs was determined and correlated to
expression of molecules known to be critical for mast cell
development by stringent statistical and pathways analysis. With
these approaches, we report a unique miRNA network that is
closely linked to the MC differentiation program. Our investiga-
tion provides novel information on the miRNA networks
interacting with one another during MC differentiation and
demonstrates how specific miRNA may potentially regulate the
crucial differentiation factors and biosynthesis of MC mediators.
Methods
Animals
Specific pathogen free BALB/c mice (6–8 weeks) were obtained
from the animal services unit of the University of Newcastle. All
experiments were performed with approval from the Animal
Ethics Committee of the University of Newcastle (Permit Number:
A-2010-136). All surgery was performed under sodium pentobar-
bital anesthesia, and all efforts were made to minimize suffering.
Culture and identification of bone marrow derived mast
cells
Bone marrow derived mast cells (BMMCs) were differentiated
and examined as previously described, with slight modifications
[23]. Briefly, mouse femurs were flushed with 5 ml ice cold HBSS
through a 70 mm cell strainer. After lysis of red blood cells and
washing with PBS, BMMCs were cultured for 6 weeks in RPMI
1640 medium (Invitrogen) supplemented with 10% FCS, 4 mM
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 25 mM
hydroxyethyl piperazineethanesulfonic acid, 1 mM sodium pyru-
vate, and 50 mM 2-mercaptoethanol, 15 ng/ml SCF (Peprotech)
and 30 ng/ml IL-3 (Peprotech) at a starting concentration of
16106 cells/ml and cultured at 37uC in a humidified atmosphere
of 5% CO2 and 95% air. Culture medium was replaced twice per
week for 6 weeks and the cell concentration was maintained at
16106 cells/ml. 2.56107 cultured cells were harvested every week
for miRNA microarray and qPCR. The purity of BMMCs was
determined by using toluidine blue staining of cytospins (16106
BMMCs per slide) and flow cytometry (See Method S1).
MicroRNA microarray
Total RNA was extracted from bone marrow cells and BMMC
cultures from week 2 to week 6 using TRIzol reagents (Life
Technologies), and miRNA microarray was performed as
previously reported [24]. Briefly, the Agilent spike-In control
was added to 100 ng RNA, which was dephosphorylated by
incubating the samples at 37uC for 30 minutes followed by ligation
of Cy3 using the Complete Labelling and Hybridisation c-Kit
(Agilent). Following ligation and drying, the Cy3-labelled RNA
samples were hybridized for 20 h at 55uC to Agilent 8615K
mouse microRNA array slides (AMADID 21828), which included
627 mouse miRNA and 39 mouse viral miRNA from the Sanger
database 12.0. After washing with Agilent gene expression wash
buffers, the hybridized microarrays were scanned on a High
Resolution C scanner (Agilent). Data were extracted from scanned
microarrays using Feature Extraction software (version 10.7.3.1).
The fluorescence index of each miRNA at different time-points
was further normalized to that of the respective miRNAs in
control group (isolated bone marrow cells). The normalized
microarray data were managed and analyzed by GeneSpring
(Agilent). MicroArray data have been deposited into ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/). The accession number is
E-MTAB-2443.
Quantification of microRNA and Messenger RNA
Quantitative polymerase chain reactions (qPCR) were per-
formed as previously described (also See Method S1) [24]. Primer
sequences are shown in Table S1.
MicroRNA target analysis
For prediction of target genes of differentially expressed
miRNAs, we first used TargetScan 6.1 (http://www.targetscan.
org/) to identify potential targets. MeSH database (http://www.
nlm.nih.gov/mesh/meshhome.html) was then employed to iden-
tify the molecules relevant to MC biology by exact syntax
matching. MiRanda (http://www.microrna.org/) was also used to
refine the predicted targets. Ingenuity Pathways Analysis (Inge-
nuity Systems, Redwood City, CA) software was employed so as to
define canonical signaling pathways containing the miRNA-
associated MC-relevant molecules, and to establish the connection
between miRNAs and their respective predicted targets.
Statistical analysis
An initial one-way ANOVA was followed by appropriate
comparisons to test for differences between means of groups.
Values are reported as the means 6 SEM for each experimental
Figure 2. Profiling the expression of miRNAs during BMMC differentiation. RNA was isolated from cultured bone marrow cells from week 2
to week 6 in the presence of SCF and IL-3, representing three independent mast cells cultures. (A) Heat map representation documenting expression
levels of 86 miRNAs identified as up- or down-regulated 5-fold or more. The fluorescence index of each miRNA at different time-points was further
normalized to that of the respective miRNAs in control group (isolated bone marrow cells). The normalized microarray data were managed and
analyzed by GeneSpring (Agilent). Scale ranges from a signal value of -6.1(blue) to +6.1(red). (B) Confirmation of miRNA array expression by Taqman
quantitative PCR. 6 miRNAs (miRNA 2132, 234a, 2223, 2466l, 2674 and let-7e) were selected to verify the expression profile of the miRNA array.
Values are presented as mean 6SEM (n= 4,6), **P,0.001 (vs. BM). *P,0.01 (vs. BM). #P,0.05 (w3 vs. w2).
doi:10.1371/journal.pone.0098139.g002
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group. The number of samples at each time-point ranged from 4
to 6. Differences in means were considered significant if p was ,
0.05.
Results
Generation of BMMC
Isolated bone marrow cells from BALB/c mice were cultured
for 6 weeks in the presence of SCF and IL-3. From week 2 to week
6, the percentage of BMMC (c-Kit+ FceRI+) in the culture was
determined first by flow cytometry. The morphological features,
the percentages and numbers of BMMCs were also determined by
toluidine blue staining of cytospin preparations. The percentage
c-Kit+FceRI+cells increased from 4.2% to 92.7% in BMMC
culture at week 6 (Fig. 1A). We observed a parallel increase in
toluidine-blue positive cells (5.3461.9% to 99.060.03%;
2.7060.216105 to 36.563.26105 cells/mL; Figs. 1B and C,
respectively.)
Distinct miRNA expression profile during BMMC
development
Given the broad involvement of miRNAs in regulating post-
transcriptional gene expression, we proceeded to determine the
miRNA profile of BMMC cultures from week 2 to week 6. Total
RNA was isolated from homogenised cells and screened as
Figure 3. Potential molecules and top canonical pathways that were predicted and targeted by the miRNAs identified as
differentially regulated during BMMC differentiation. (A) Target prediction by TargetScan database (http://www.targetscan.org/) was
established on sequence data complementarity to target 39UTR sites. Target molecules, associated with MC biology, were identified by exact syntax
matching in the MeSH database (http://www.nlm.nih.gov/MeSH/MeSHhome.html). (B) Top 30 canonical pathways that include selected 524
molecules as identified by IPA. The significance of association between selected genes and canonical pathway was evaluated by a right-tailed Fisher’s
exact test (grey bars, upper y-axis). Ratios referring to the proportion of selected genes from a pathway related to the total number of molecules that
make up that particular pathway were also displayed (line graph, bottom y-axis).
doi:10.1371/journal.pone.0098139.g003
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described in Methods. We identified eighty-six (86) miRNAs
characterised with 5-fold differential expression during BMMC
development; among these, we document 45miRNAs with increased
expression and 41 with decreased expression, respectively (Fig. 2 A).
Detailed information describing these miRNAs is included in Table
S2 in File S1. We validated the differential expression of six (6) of
the 86 miRNAs with qPCR (Fig. 2 B). Among the miRNAs selected
for validation, miR-223 has a central role myeloid cell development
[25]. The other miRNAs have been linked to cell development,
inflammation and disease [26–30]. The expression profiles defined
for these six miRNAs by qPCR were consistent with the expression
patterns documented on the microarray.
Analysis of BMMC related molecules and canonical
pathways potentially regulated by the miRNAs
In an effort to elucidate targets and pathways regulated by the
86 differentially-expressed miRNAs, we proceeded to identify
Figure 4. Expression levels of IL-3Ra, c-Kit and FceRIa correlated with the expression of miRNAs that might target these transcripts.
Data represent findings from three independent mast cell cultures. (A) Expression levels of IL-3Ra, c-Kit and FceRIa were determined by qPCR. (B)
Potential miRNAs targeting the 39-UTR of c-Kit and FceRIa were identified by TargetScan, MiRanda database and IPA ingenuity system. Blue
represents decreased expression of miRNAs, whereas yellow is for increased expressed miRNAs. (C) The fold changes of potential regulating miRNAs
were calculated based on the fluorescence index of each miRNA at different time-points, after normalization to that of the respective miRNAs in the
control group (isolated bone marrow cells). Values are presented as mean 6SEM (n= 4,6), **P,0.001 (vs. BM). *P,0.01 (vs. BM).
doi:10.1371/journal.pone.0098139.g004
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putative mRNA targets using TargetScan (version 6.1). TargetS-
can is a search engine that predicts targets for miRNA-mRNA
interactions in eukaryotes; the algorithms search for 8- and 7-mer
sites located in the 39-UTR regions of mRNAs which share
sequence homology with query miRNA sequences [31]; predic-
tions are then ranked by their probability of targeting the mRNA
transcript [32]. We used a 95th percentile cutoff to predict the
potential targets. With this method, we identified 5924 mRNA
transcripts that could be targeted by the 86 miRNAs (Fig. 3 A).
The target mRNAs were further refined by searching the MeSH
database, in an effort to link gene expression data with known
MC-related pathways, diseases and phenotypes. There were 1418
mRNAs identified by MeSH database as containing the exact
terms ‘‘mast cell, SCF, IL-3 and tryptase’’ with a link to at least
one PubMed-affiliated reference. We then plotted differences in
distribution of mRNAs predicted by TargetScan and MeSH
databases, and found that, of the original 5924 mRNA transcripts,
we could focus on 524 that were targeted by both search methods
(Table S3 in File S1).
These 524 MC mRNAs were then organized and classified with
the assistance of Ingenuity Pathways Analysis (IPA); the top 30
canonical pathways were listed (Fig. 3 B; Table S4 in File S1).
Two-hundred and three (203) of the aforementioned molecules
(38.7% of the 524 MC-associated transcripts) were included within
these top 30 canonical pathways. Although many of the pathways
are commonly involved in cell death and survival or proin-
flammatory activity, these pathways also include those that
contribute to mast cell differentiation and function. For example,
Phosphatase and Tensin Homolog (PTEN) regulates the prolif-
eration MC; PTEN deficiency results in a mastocytosis-like
proliferative disease [33]. Likewise, activation of Glucocorticoid
Receptor signaling suppresses both proliferation and degranula-
tion of MCs [34], and PI3/AKT signaling is critical for the
maturation and pro-inflammatory factor production by MC [35].
Pathways such as Growth Hormone, IGF-1, Apoptosis and Role
of JAK2 in Hormone-Like Cytokine may regulate MC survival
and death [8]. FLT3 Signaling in Hematopoietic Progenitor
Cells, Erythropoietin, IL-6 and ErbB signaling may play central
roles in differentiation of haematopoietic progenitor cells to MC
specific lineage [36]. Well-known inflammatory pathways such as
Acute Phase Response and NF-kB likewise regulate the
production of proinflammatory factors in MCs, and NF-kB can
also modulate MC proliferation [37,38]. TREM1 may play a
central role in MC responses to bacterial invasion [37].
Interestingly, activation of MCs has long been recognized as an
important component of the pathogenesis of rheumatoid arthritis
[39]; the two signaling pathways, Role of Osteoblast/Osteoclast
and Chondrocytes in Rheumatoid Arthritis and Role of
Macrophages/Fibroblast and Endothelial Cell in Rheumatoid
Arthritis, may feature components of this role. Taken together,
these data suggest important roles for miRNAs in the regulation
of trafficking, biological function and cell death/cell survival of
BMMCs.
Multiple miRNAs are linked to the expression of c-Kit and
FceRI but not IL-3Ra
IL-3Ra, c-Kit and FceRI are critical signature receptors of
MCs; we examined the expression of these molecules in BMMC
cultures from week 2 to week 6 by qPCR (Fig. 4 A). Relative
expression of transcripts encoding IL-3Ra underwent a small but
statistically significant increase between week 2 and week 5. By
contrast, expression levels of c-Kit and FceRIa increased markedly
(greater than 40-fold over baseline by week 6). We used IPA and
the miRanda database in order to determine whether any of the
86 differentially expressed miRNAs (Fig. 2 A) might have binding
sequences that could target the 39-UTRs of any of these specific
transcripts. Interestingly, none of the aforementioned 86 miRNAs
has any clear potential to regulate IL-3Ra. However, the c-Kit
transcript is linked to 6 specific miRNAs, of which 3 (miR 2218,
2505 and -542-3p) undergo an increase and 3 (miR -130a, -223
and -421) a decrease (Fig. 4 B and C) during BMMC
differentiation in culture. The transcript encoding FceRI may be
targeted by miR-363. The 39-UTR binding sites of these miRNAs
are included in Table S5 in File S2.
Critical MC transcriptional regulators targeted by distinct
sets of miRNAs
The fate of BMMCs is critically determined by a coordinated
action by transcription factors Mitf, GATA1, c/EBPa and PU.1
[17,18]. We evaluated the differential expression of these factors
by qPCR and correlated these patterns to those of the 86
differentially expressed miRNAs (Fig. 2 A). As previously reported
[15,16], expression levels of Mitf and GATA1 were significantly
elevated during differentiation of BMMCs while that of c/EBPa
decreased dramatically (Fig. 5 A). PU.1 expression did not
change, although it was highly expressed overall in BMMC culture
(data not shown). Using IPA and miRanda, we identified three sets
of miRNAs that have to potential to regulate the expression of
these four MC transcriptional regulators (Fig. 5 B). We correlated
the expression levels of specific miRNAs to Mitf (miR 2181d,
2207, 2298, 2342-3p, 2710 and 21896), GATA1 (let-7e, miR
2196b, 139–5p, 2200b and 2290–5p) and c/EBPa (miR 2129–
3p, 2218, 2330, 2363, 2672, 1894–3p and 671-5p), but
interestingly, found no miRNAs with the capacity to target PU.1
(Fig. 5 C). The 39-UTR binding sites of miRNAs that target all
three of these mRNAs are shown in Table S6 in File S2. These
findings likewise suggest that miRNAs have the potential for
extensive and critical involvement in the regulation of MC
differentiation.
miRNAs connected to the expressions of STAT3, STAT5a,
STAT5b, GATA2 and GATA3
We proceeded to determine whether any of the 86 differentially-
expressed miRNAs could target other factors that have been
implicated in the regulation of MC differentiation. STAT3 and
STAT5a/b play pivotal roles in transducing signals associated
with SCF and IL-3 induction of MC differentiation [1]. The
transcription factors GATA2 and GATA3 are also important in
promoting differentiation of MCs from bone marrow-derived
Figure 5. Expression of Mitf, GATA1 and c/EBPa correlated to the expression levels of miRNAs that potentially target these
transcripts. (A). Expression levels of Mitf, GATA1 and c/EBPa were determined by qPCR. (B) Potential miRNAs targeting the 39-UTR of Mitf, GATA1
and c/EBPa were identified by TargetScan and Miranda database and IPA ingenuity system. Blue represents decreased expression of miRNAs, whereas
yellow is for increased expressed miRNAs. (C). The fold changes of potential regulating miRNAs were calculated based on the fluorescence index of
each miRNA at different time-points, after normalization to that of the respective miRNAs in the control group (isolated bone marrow cells). Values
are presented as mean 6SEM (n= 4,6), **P,0.001 (vs. BM). *P,0.01 (vs. BM).
doi:10.1371/journal.pone.0098139.g005
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myeloid progenitors [1,16–18]. We first determined the expression
levels of STAT3, STAT5a, STAT5b, GATA2 and GATA3
during BMMC culture (Fig. 6 A). All of these factors responded to
culture conditions with increased expression from week 2 to week
6. Interestingly, the miRNAs that targeted these mRNA
transcripts (Fig. 6 B), further refined by IPA and miRanda
analysis, mostly overlapped with those identified in Fig. 5B and
Fig. 6B. The interactions between the 39-UTRs of these five
mRNAs and their associated miRNAs are presented in Table S7
in File S2. For STAT3, the two of the three associated miRNAs
(miR 2330 and 2874) responded with increased expression and
one (miR-125b-5p) decreased; for STAT5b, two miRNAs (miR
2125b-5p and 2342-3p) responded with decreased expression
and one (miR-23b) increased (Fig. 6 C). Decreased expression of
miR-342-3p was also associated with increased levels of STAT5a,
and we found that one factor, miRNA-132, may concurrently
target STAT5b, GATA2 and GATA3. Notably, there is
considerable overlap between the miRNAs that regulate the three
core transcription factors (Fig. 5), and the aforementioned STATs
and GATA2/GATA3 regulators (Fig. 6). The distinct role of
these miRNAs in fine-tuning the expression of these molecules in
MC differentiation remains to be explored.
Association between miRNAs expression and major
functional transcripts of BMMC
MC granules contain substantial amounts of heparin, histamine,
MC-specific proteases (tryptase and chymase) and other unique
biological factors [7]. N-deacetylase/N-sulfotransferase (Ndst) 2 is
a crucial enzyme in the biosynthetic pathway of heparin and its
expression is strongly linked to the process of MC maturation [40].
Likewise, histamine is synthesized by an enzymatic reaction
catalyzed by L-histidine decarboxylase (HDC), while MC prote-
ases are each encoded by the unique genes, mast cell protease
(mMCP) 22, 24, 25, 26 and 27 [7]. We determined that
transcripts encoding Ndst2, mMCP6 and mMCP7 were signifi-
cantly up-regulated from week 2 to week 6, whereas the expression
of myeloperoxidase (MPO, predominantly expressed in neutro-
phils) decreased to nearly undetectable levels at wk 6 (Fig. 7 A).
HDC was constantly expressed at high levels over the same
interval (unpublished observation). Mouse MCP4 increased
marginally at week 2 but was down-regulated to 21% of initial
levels by week 6 (Fig. 7 A). Ndst2 expression was linked to that of
three miRNAs (let-7e, miR 2211 and 2207) that showed
increased expression and three miRNAs (miR 2135a, 2671-5p
and 21894-3p) with decreased expression (Fig. 7 B and C), while
mMCP4 was associated with the increased expression of 5
miRNAs (miR 2132, 2330, 501-3p, 542-3p and 2672) and the
decreased expression of miR-1894-3p (Fig. 7 B and C). MPO and
mMCP6, were targeted by miR-207 and miR-705 which had
increased and decreased expression, respectively. The interaction
between 39-UTR of the four mRNAs and their associated
miRNAs are presented in Table S8 in File S2. Interestingly,
the sequence of miR-1893-3p suggests that it is likely to target both
Ndst2 and mMCP4.
Discussion
Previous studies have identified several miRNAs, including miR
-132, miR-146a and miR-221, that play roles in regulating MC
apoptosis, cell cycle regulation, growth and degranulation [41–43].
Monticelli and colleagues have used 181-miRNAs-Array to profile
matured BMMC and identified 15 of them with detectable
changes. However, their method can not efficiently discriminate
between close miRNA paralogs [44]. As a more recent example,
Lee and colleagues have shown that decreased expression of both
miR-539 and miR-381 in association with c-Kit signaling
promotes expression of the transcription factor, Mitf, which leads
to MC proliferation [45]. Our present study was undertaken in
order to provide a comprehensive examination of miRNA
temporal expression during differentiation of BMMC in culture
starting within the initiation of differentiation in cellular milieu of
the BM, with more extensive and gene-specific Agilent Array
containing 627 mouse miRNA and 39 mouse viral miRNA. Then
by using detailed pathway analysis programs we have linked
miRNAs expression in cultures enriched in differentiating mast
cells with the regulation of transcripts that play critical roles in
mast cell development. Toward this end, we have established a
BMMC ex vivo culture system and we have determined the
expression of characteristic receptors, functional factors and
critical transcription regulators during the development. The
profile of expressed miRNAs was determined over time and
correlated to expression of molecules known to be crucial to MC
development by stringent statistical and validated pathways
analyses. Via these methods, we documented an original MC
expression signature that included 86 independent miRNAs that
were differentially regulated five-fold or more over baseline levels
during the development of BMMC between week 2 and week 6.
MiRNAs play critical roles in maintaining gene expression at
appropriate levels and in fine-tuning a wide range of biological and
disease processes [20–22]. However, it remains difficult to
associate miRNAs with their targets either directly or experimen-
tally and likewise to predict specific biological functions. For
example, Siemens and colleagues have determined that c-Kit is a
direct target of miR-34a by using several human colorectal cancer
cell lines [46]. Although miR-34a has two continuous 8-mer
binding sites at the 3-UTR of human c-Kit, it may bind weakly to
the respective region of mouse c-Kit as there are only two
discontinuous 5-mer seed sequences. This suggests that miR-34a is
unlikely to directly regulate the expression of c-Kit in mouse.
Interestingly, Shin and colleagues have identified that miR-34a
contributes to BMMC apoptosis by targeting Bcl-2 [47]. These
observations may show that the potential targets of miRNAs can
be rather distinctive and these small regulatory molecules play
fairly distant regulatory roles in biological development and the
progression of diseases in different species.
Here, we have employed a combinatorial approach, and we
searched for targets for the 86 differentially-regulated miRNAs
initially based on algorithms from TargetScan and further filtered
the potential targets by searching MeSH database for published
links to MC biology. From there, our findings were refined and
categorized into networks that associated miRNAs with critical
MC factors using miRanda and IPA. With this approach, we have
Figure 6. Expression of STAT3, STAT5a/b, GATA2 and GATA3 correlated to the expression of miRNAs that potentially target these
transcripts. (A). Expression levels of STAT3, STAT5a/b, GATA2 and GATA3 were determined by qPCR. (B). Potential miRNAs targeting the 39-UTR of
STAT3, STAT5a/b, GATA2 and GATA3 were identified by TargetScan and MiRanda database and IPA ingenuity system. Blue represents decreased
expression of miRNAs, whereas yellow is for increased expressed miRNAs. (C). The fold changes of potential regulating miRNAs were calculated based
on the fluorescence index of each miRNA at different time-points, after normalization to that of the respective miRNAs in the control group (isolated
bone marrow cells). Values are presented as mean 6SEM (n= 4,6), **P,0.001 (vs. BM). *P,0.01 (vs. BM).
doi:10.1371/journal.pone.0098139.g006
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Figure 7. Expression of Ndst2, MPO, mMCP4 and mMCP6 correlated to the expression of miRNAs that potentially target these
transcripts. (A) Expression levels of Ndst2, MPO, mMCP4 and mMCP6 were determined by qPCR. (B) Potential miRNAs targeting the 39-UTR of Ndst2,
MPO, mMCP4 and mMCP6 were identified by TargetScan and Miranda database and IPA ingenuity system. Blue represents decreased expression of
miRNAs, whereas yellow is for increased expressed miRNAs. (C) The fold changes of potential regulating miRNAs were calculated based on the
fluorescence index of each miRNA at different time-points, after normalization to that of the respective miRNAs in the control group (isolated bone
marrow cells). Values are presented as mean 6SEM (n= 4,6), **P,0.001 (vs. BM). *P,0.01 (vs. BM).
doi:10.1371/journal.pone.0098139.g007
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identified 32 unique miRNAs that are most likely to be involved in
regulating MC differentiation and function via targeting critical
MC factors.
By cross-comparison with TargetScan and MeSH database, we
generated a list of 524 transcripts that have the highest-likelihood
of serving as targets for the 86 differentially-expressed miRNAs
and linked to MC biology. By IPA, we showed that 39% of these
molecules were included within the top 30 signal transduction
pathways, among which were molecules controlling cell cycle,
growth and death, and cell activation. For example, PTEN and
PI3K/AKT signaling are closely paired and serve to balance one
another in order to regulate cell proliferation. Impairment of
PTEN signaling may lead to PI3K/AKT hyperreactivity, resulting
reduced apoptosis and unchecked cell proliferation [33]. Further-
more, miRNA may also target other pathways such as growth
hormone, IGF-1 and FLT3 signaling to control MC differentia-
tion. JAK/STAT and NF-kB signal transduction pathways that
are responsible for cell differentiation and are pro-inflammatory
are also potentially targeted by the identified miRNAs.
By examining connectivity between predicted targets, we
distinguished between closely-linked molecules that may operate
as network hubs, with highly associated factors functioning as
similar units. Among the 524 potential miRNA targets, c-Kit and
FceRIa are the well-known signature receptors of MC [1,9,10].
The expression of c-Kit and FceRIa were increased almost 400-
fold from day 0 through 6 weeks of culture (Fig 5. A). These results
are consistent with the greatly expanded c-Kit+ FceRIa+ BMMC
population. Although SCF and IL-3 are used for 4 to 8 weeks in
most ex vivo BMMC cultures [8–13,23], we have observed that
none of 86 miRNAs target the IL-3Ra chain transcripts. However,
transcripts for this receptor were only slightly increased during
culture and levels were high prior to induction of differentiation
indicating that this system was already functional (data not shown).
Taken together, these results suggest that the IL-3 signaling
pathway may be involved more broadly in myeloid differentiation
and its contributions are not necessarily limited to MC maturation.
By contrast, the interactions between SCF and c-Kit are essential
for MC development; deleting c-Kit in a mouse model results in
the deficiency of mast cells and elimination of IgE-mediated
responses [12,13]. Six miRNAs were closely associated to c-Kit
expression during MC differentiation; miR 2218, 2421 and
2542-3p recognize multiple sites in the 39-UTR (Table S4 in
File S1), suggesting that these miRNAs are critical for MC
function. Furthermore, it appears that the expression of FceRIa is
only regulated by miR-363 from this dataset.
As per current models, cooperation between several transcrip-
tional regulators determines the differentiation and function of
mast cells [1,16–18]. Our results suggest that three core
transcriptional factors, Mitf, GATA1 and c/EBPa are differen-
tially regulated by distinct groups of miRNAs (Fig. 6). The level of
PU.1, which is another core regulator, did not change during
BMMC culture, but levels of transcript remained high throughout
(data not shown). Of note, there are other transcriptional factors
involved in MC differentiation, such as STAT3, STAT5a/b and
GATA2/3 [1,16–18]. Indeed, appropriate activation of these
transcriptional pathways in cell growth, differentiation, survival,
chemotaxis and cytokine production is essential for MC growth
and differentiation [1,16–18]. Unlike the discrete connection
between the distinct groups of miRNAs and Mitf, GATA1 and c/
EBPa, the relationship between the STAT and GATA transcripts
and miRNAs is more difficult to define (Fig. 7). This is partly
because these proteins are directly activated by SCF and IL-3, and
partly because that the activation of these transcription factors is
largely regulated by their phosphorylation, rather than directly by
increased protein expression. Nevertheless, it is noteworthy that
miR-342-3p -with almost 1000-fold decreased expression- still
targets STAT5a, STAT5b and Mitf. Furthermore, miR-125b-5p,
that was decreased approximately 200 fold, is associated with the
increased expression of STAT3 and STAT5b transcripts. This
suggests that the down-regulation of the two aforementioned
miRNAs potentially play critical roles in MC differentiation,
particularly in the early phases of lineage commitment. On the
contrary, miR-132 was significantly increased, but its potential
targets (e.g. STAT5b and GATA2/3) were also increased. These
findings suggest that miR-132 acts as an important checkpoint to
maintain the expression of these transcriptional regulators at
appropriate levels. Interestingly, miR-132 may also control the
expression of the mast cell protease, mMCP-4, suggesting the
broader roles for this miRNA in the MC biology.
Finally, to explore the connections between miRNAs and MC
secretory function, we examined associations between selected
miRNAs and the 39UTRs of major MC secretory mediators.
Among the thirteen miRNAs identified, interestingly, three
miRNAs (miR 2211, 2501-3p and 2705) were only linked to
Ndst2, mMCP4 and mMCP6, respectively (Fig. 7). Not only with
selected MC secretory mediators, seven of aforementioned 13
miRNAs (let-7e, miR 2207, 2298, 2330, 2671-5p, 2672 and
21894-3p) were also associated with three core MC transcrip-
tional regulators (Mitf, GATA1 and c/EBPa) (Figs. 6 and 8).
Collectively, our data suggest that the molecular mechanisms
controlling MC differentiation and function are closely interwoven
where sets of miRNA play central roles.
Taken together, we present a model of BMMC differentiation
via which we can examine expression patterns of miRNAs. We
have analysed these patterns and identified miRNAs that may play
pivotal roles in driving MC maturation and regulating MC
function. However, to understand how these selected miRNAs
interact with their targets, functional studies with miRNA
targeting, knock-in and knock-down models are required. Never-
theless, we are able to demonstrate that these selected miRNAs
can be grouped as networks in order to guide bone marrow cells
toward MC development in cooperation with cytokine signaling.
Furthermore, there are also a number of intracellular signaling
pathways that may be regulated by these miRNAs. Manipulating
the expression of these miRNAs may promote further under-
standing of the underlying mechanisms that are critical for MC
differentiation and function, and ultimately provide therapeutic
targets for treating MC-associated diseases.
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